Zhen-Qiang Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhen-Qiang Qi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aoxue Zhao
School of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, Shandong, 272067, People’s Republic of China
1 shared publication - Canlei Zheng
School of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, Shandong, 272067, People’s Republic of China
1 shared publication - Cong Han
Nephropathy Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
1 shared publication - Jiahui Liu
School of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, Shandong, 272067, People’s Republic of China
1 shared publication - Jingna Fan
School of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, Shandong, 272067, People’s Republic of China
1 shared publication - Rong Wang
School of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, Shandong, 272067, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-21
Berberine Ameliorates Diabetic Kidney Disease by Modulating Macrophage Polarization via Inhibiting IL-17A Signaling
Objective: This study aimed to elucidate the molecular mechanisms of berberine (BBR) in ameliorating diabetic kidney disease (DKD), focusing on its regulatory effects on the renal immune microenvironment and macrophage polarization. Methods: We first employed a network pharmacology approach, integrating public transcriptomic data with drug target databases, to predict the core pathways and immune regulatory mechanisms of BBR in DKD. To experimentally validate these in silico predictions, we assessed the effects of BBR on apoptosis, fibrosis, and inflammation in a high-glucose-induced renal tubular epithelial cell (NRK-52E) model. Finally, a DKD rat model was established to confirm the therapeutic efficacy in vivo and to mechanistically investigate BBR’s impact on renal macrophage polarization and the key signaling proteins of the predicted pathway. Results: Network pharmacology and transcriptomic analysis identified 55 core genes of BBR in DKD, enriched in apoptosis, metabolism, oxidative stress, and inflammation, with immune infiltration implicating T cells, B cells, and macrophage subsets. In vitro, BBR enhanced viability of high-glucose–injured NRK-52E cells, suppressed apoptosis and fibrosis markers, and reduced IL-6, IL-17A, and TNF-α levels. In vivo, BBR reduced hyperglycemia, preserved renal function, attenuated fibrosis, and rebalanced macrophage polarization by inhibiting M1 while promoting M2 phenotypes. Mechanistically, these effects were associated with downregulation of the IL17A/TRAF6/MAPK14 pathway. Conclusion: Berberine alleviates diabetic kidney disease by regulating macrophage polarization via inhibition of the IL17A/TRAF6/MAPK14 signaling pathway, underscoring its therapeutic potential as an anti-inflammatory and anti-fibrotic agent.
- 1 March 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-21
Open AccessBerberine Ameliorates Diabetic Kidney Disease by Modulating Macrophage Polarization via Inhibiting IL-17A Signaling
Objective: This study aimed to elucidate the molecular mechanisms of berberine (BBR) in ameliorating diabetic kidney disease (DKD), focusing on its regulatory effects on the renal immune microenvironment and macrophage polarization. Methods: We first employed a network pharmacology approach, integrating public transcriptomic data with drug target databases, to predict the core pathways and immune regulatory mechanisms of BBR in DKD. To experimentally validate these in silico predictions, we assessed the effects of BBR on apoptosis, fibrosis, and inflammation in a high-glucose-induced renal tubular epithelial cell (NRK-52E) model. Finally, a DKD rat model was established to confirm the therapeutic efficacy in vivo and to mechanistically investigate BBR’s impact on renal macrophage polarization and the key signaling proteins of the predicted pathway. Results: Network pharmacology and transcriptomic analysis identified 55 core genes of BBR in DKD, enriched in apoptosis, metabolism, oxidative stress, and inflammation, with immune infiltration implicating T cells, B cells, and macrophage subsets. In vitro, BBR enhanced viability of high-glucose–injured NRK-52E cells, suppressed apoptosis and fibrosis markers, and reduced IL-6, IL-17A, and TNF-α levels. In vivo, BBR reduced hyperglycemia, preserved renal function, attenuated fibrosis, and rebalanced macrophage polarization by inhibiting M1 while promoting M2 phenotypes. Mechanistically, these effects were associated with downregulation of the IL17A/TRAF6/MAPK14 pathway. Conclusion: Berberine alleviates diabetic kidney disease by regulating macrophage polarization via inhibition of the IL17A/TRAF6/MAPK14 signaling pathway, underscoring its therapeutic potential as an anti-inflammatory and anti-fibrotic agent.
- Open Access
- 21 July 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-16
Study on the Antihypertensive Mechanism of Astragalus membranaceus and Salvia miltiorrhiza Based on Intestinal Flora-Host Metabolism
Our previous studies have shown that the combination of Astragalus membranaceus and Salvia miltiorrhiza (HD) had a good antihypertensive effect, but its potential mechanism remained unclear. This study aimed to investigate the role of intestinal flora and serum metabolism induced by HD against hypertension. 16 spontaneous hypertensive rats (SHRs) were divided into HD group (5.9 g/kg) and model group (M) (normal saline), with eight Wistar-Kyoto (WKY) rats as control group (W) (normal saline). Rats were fed by gavage once a day for 28 days. The changes of intestinal flora and serum metabolism were analyzed by 16S rDNA sequencing and LC-MS/MS assay. HD decreased blood pressure steadily, improved the structure and composition of imbalance flora in SHRs, increased the abundance and diversity of flora, and decreased flora Firmicutes to Bacteroidetes (F/B) ratio. Rumen bacterium NK4A214, Clostridium sp. MC 40 increased remarkably in M group. Akkermansia, Akkermansia muciniphila, and Lactobacillus intestinalis increased significantly in HD group, which were functionally related to the significant increase of Lachnoclostridium, Faecalibaculum, and Lactobacillus reuteri in W group, which were all probiotics producing butyric acid, lactic acid, and regulating inflammation and other antihypertensive related factors. HD also changed the serum metabolic pattern of SHRs. 16 potential biomarkers related to inflammation, vasodilation, steroid hormones, oxidative stress, and etc. changed significantly, mainly enriched in arachidonic acid metabolism, tryptophan metabolism, steroid hormone biosynthesis, and glutathione metabolism. The correlation analysis demonstrated that the dominant genius and species in three groups were highly correlated with steroid hormone biosynthesis, arachidonic acid metabolism, tryptophan metabolism, and vitamin B6 metabolism. Our research indicated that HD had a good antihypertensive effect, which may be driven by the protective intestinal flora and beneficial metabolites induced by it, and the metabolites were closely related to the changes of intestinal flora. It provided new insights for the antihypertensive mechanism of HD.
- 21 July 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1-16
Open AccessStudy on the Antihypertensive Mechanism of Astragalus membranaceus and Salvia miltiorrhiza Based on Intestinal Flora-Host Metabolism
Our previous studies have shown that the combination of Astragalus membranaceus and Salvia miltiorrhiza (HD) had a good antihypertensive effect, but its potential mechanism remained unclear. This study aimed to investigate the role of intestinal flora and serum metabolism induced by HD against hypertension. 16 spontaneous hypertensive rats (SHRs) were divided into HD group (5.9 g/kg) and model group (M) (normal saline), with eight Wistar-Kyoto (WKY) rats as control group (W) (normal saline). Rats were fed by gavage once a day for 28 days. The changes of intestinal flora and serum metabolism were analyzed by 16S rDNA sequencing and LC-MS/MS assay. HD decreased blood pressure steadily, improved the structure and composition of imbalance flora in SHRs, increased the abundance and diversity of flora, and decreased flora Firmicutes to Bacteroidetes (F/B) ratio. Rumen bacterium NK4A214, Clostridium sp. MC 40 increased remarkably in M group. Akkermansia, Akkermansia muciniphila, and Lactobacillus intestinalis increased significantly in HD group, which were functionally related to the significant increase of Lachnoclostridium, Faecalibaculum, and Lactobacillus reuteri in W group, which were all probiotics producing butyric acid, lactic acid, and regulating inflammation and other antihypertensive related factors. HD also changed the serum metabolic pattern of SHRs. 16 potential biomarkers related to inflammation, vasodilation, steroid hormones, oxidative stress, and etc. changed significantly, mainly enriched in arachidonic acid metabolism, tryptophan metabolism, steroid hormone biosynthesis, and glutathione metabolism. The correlation analysis demonstrated that the dominant genius and species in three groups were highly correlated with steroid hormone biosynthesis, arachidonic acid metabolism, tryptophan metabolism, and vitamin B6 metabolism. Our research indicated that HD had a good antihypertensive effect, which may be driven by the protective intestinal flora and beneficial metabolites induced by it, and the metabolites were closely related to the changes of intestinal flora. It provided new insights for the antihypertensive mechanism of HD.